The Filing Desk

Insight Molecular Diagnostics vs VolitionRx

Insight Molecular Diagnostics IMDX · VolitionRx VNRX · Health Care Supplies

Insight Molecular Diagnostics reported revenue of $4 million in fiscal 2025, 2.4 times VolitionRx's $2 million in fiscal 2025. Insight Molecular Diagnostics' revenue grew 115.6% in its latest year, and VolitionRx's grew 40.0%. Insight Molecular Diagnostics had an operating margin of -1260.8%, against -1258.5% at VolitionRx. Free cash flow was −$25 million at Insight Molecular Diagnostics and −$20 million at VolitionRx.

Side by side

Insight Molecular DiagnosticsVolitionRx
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$4M$2M
Revenue growth115.6%40.0%
Revenue growth a year, last 5 years27.9%—
Gross margin56.7%—
Operating margin−1,260.8%−1,258.5%
Net margin−1,238.5%−1,352.2%
Free cash flow−$25M−$20M
Free cash flow margin−625.6%−1,144.7%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count133.2%23.5%
Last close$1.66$0.16
P/E at the last close——
Insider trades, last 12 monthsbought $11.7 million, sold $0—
Piotroski F-score—2 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Insight Molecular DiagnosticsVolitionRx
Operating margin
Percent of revenue
Insight Molecular DiagnosticsVolitionRx
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Insight Molecular DiagnosticsVolitionRx

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Insight Molecular Diagnostics and VolitionRx pages.